Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2006

View Archived Issues

Bryostatin 1 provides protection against ischemia/reperfusion injury

Orally available novel nucleotide is active against drug-resistant HIV-1 mutants

Updated profile of ARD-353, a cardioprotective nonpeptide delta opioid receptor agonist

Tadalafil improves neurological function in a preclinical stroke model

Initial preclinical data for ReN-004 stem cell lines for Parkinson's disease

Three registrational phase III trials of Erbitux complete enrollment

New phase III trial studies Nexavar in NSCLC

17beta-Estradiol targets STAT3 to provide neuroprotection following stroke

Dana-Farber Cancer Institute to study CTCE-9908 for brain cancer

BioInvent reassigns rights to develop osteoarthritis drugs to Cartela

CFFT to continue support for Copernicus' gene therapy for cystic fibrosis

New studies suggest Ampligen and Alferon may protect against avian flu

NNZ-4921 shows promise in rat peripheral neuropathy model

Results of studies investigating AAGP effect on cellular growth and function

Orphan drug designation for Coramsine for melanoma

Targeting gamma-secretase provides neuroprotection in preclinical stroke

Novel compounds with possible utility in the treatment of cancer revealed

Preclinical and clinical data on JTK-303/GS-9137 disclosed

New therapeutic agents for acne disclosed in recent Galderma patent

Rho kinase inhibitors prepared and tested at GlaxoSmithKline

CD38-derived peptide shows potent anti-HIV-1 activity in vitro

New HIV protease inhibitor shows promise for multidrug-resistant HIV infection

Pilot bioavailability testing of CDT extended release ondansetron tablets

Vusion approved for treatment of diaper dermatitis complicated by candidiasis

Hycamtin sNDA accepted for priority review

Rimonabant receives approvable, nonapprovable letters

FDA approval for new oral contraceptive Loestrin 24 Fe

CE Mark for CoStar paclitaxel-eluting stent

Alvesco approved in Europe for mild to severe persistent asthma in adolescents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...